http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106267198-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0052 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate | 2016-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106267198-B |
| titleOfInvention | It targets photo-thermal therapy combined immunization and treats antitumor compound formulation and the preparation method and application thereof |
| abstract | Combined immunization is treated the present invention relates to a kind of targeting photo-thermal and treats antitumor compound formulation and the preparation method and application thereof, is made of Cypate liposome, adriamycin-bovine serum albumin(BSA) (ADM-BSA) and hyaluronic acid-adriamycin (HA-ADM).Cypate is substantially better than free Cypate by chemical stability after liposome entrapment, and external temperature rise effect is stronger, has good tumor-targeting and photo-thermal therapy effect.The targeting of Cypate liposome is good, with stronger photo-thermal therapy effect, dual-target hyaluronic acid-haptens immune formulation of immunization therapy and active targeting chemotherapy is constituted in conjunction with ADM-BSA and HA-ADM, remaining for deep and transfer tumour cell therapeutic effect is good, it can achieve the purpose that synergistic treatment to avoid the defect in respective treatment. |
| priorityDate | 2016-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.